Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics

References

• TsuruoTNaitoMTomidaAMolecular targeting therapy of cancer: drug resistance, apoptosis and survival signalCancer Sci200394152112708468
   PubMed Web of Science ®Google Scholar
• AmbudkarSVDeySHrycynaCARamachandraMPastanIGottesmanMMBiochemical, cellular, and pharmacological aspects of the multidrug transporterAnnu Re Pharmacol Toxicol199939361398
   PubMed Web of Science ®Google Scholar
• SchinkelAHJonkerJWMammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overviewAdv Drug Deliv Rev20035532912535572
   PubMed Web of Science ®Google Scholar
• GottesmanMMLingVThe molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein researchFEBS Lett2006580998100916405967
   PubMed Web of Science ®Google Scholar
• RobeyRWIeranoCZhanZBatesSEThe challenge of exploiting ABCG2 in the clinicCurr Pharm Biotechnol20101259560821118093
   PubMed Web of Science ®Google Scholar
• AllenJDSchinkelAHMultidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2)Mol Cancer Ther2002142743412477055
   PubMed Web of Science ®Google Scholar
• DoyleLAYangWAbruzzoLVA multidrug resistance transporter from human MCF-7 breast cancer cellsProc Natl Acad Sci U S A19989515665156709861027
   PubMed Web of Science ®Google Scholar
• AllikmetsRSchrimlLMHutchinsonARomano-SpicaVDeanMA human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistanceCancer Res199858533753399850061
   PubMed Web of Science ®Google Scholar
• BrangiMLitmanTCiottiMCamptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cellsCancer Res1999595938594610606239
   PubMed Web of Science ®Google Scholar
• MaliepaardMvan GastelenMAde JongLAOverexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell lineCancer Res1999594559456310493507
   PubMed Web of Science ®Google Scholar
• RossDDKarpJEChenTTDoyleLAExpression of breast cancer resistance protein in blast cells from patients with acute leukemiaBlood20009636536810891476
   PubMed Web of Science ®Google Scholar
• SteinbachDSellWVoigtAHermannJZintlFSauerbreyABCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemiaLeukemia2002161443144712145683
   PubMed Web of Science ®Google Scholar
• van den Heuvel-EibrinkMMWiemerEAPrinsAIncreased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)Leukemia20021683383911986944
   PubMed Web of Science ®Google Scholar
• BenderraZFaussatAMSayadaLBreast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemiasClin Cancer Res2004107896790215585622
   PubMed Web of Science ®Google Scholar
• PlasschaertSLVan Der KolkDMDe BontESVellengaEKampsWADe VriesEGBreast cancer resistance protein (BCRP) in acute leukemiaLeuk Lymphoma20044564965415160935
   PubMed Web of Science ®Google Scholar
• SuvannasankhaAMindermanHO’LoughlinKLBreast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and functionLeukemia2004181252125715208643
   PubMed Web of Science ®Google Scholar
• UgglaBStahlEWagsaterDBCRP mRNA expression v. clinical outcome in 40 adult AML patientsLeuk Res20052914114615607361
   PubMed Web of Science ®Google Scholar
• HonjoYHrycynaCAYanQWAcquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cellsCancer Res2001616635663911559526
   PubMed Web of Science ®Google Scholar
• VolkELFarleyKMWuYLiFRobeyRWSchneiderEOverexpression of wild-type breast cancer resistance protein mediates methotrexate resistanceCancer Res2002625035504012208758
   PubMed Web of Science ®Google Scholar
• AllenJDJacksonSCSchinkelAHA mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistanceCancer Res2002622294229911956086
   PubMed Web of Science ®Google Scholar
• OzvegyCVaradiASarkadiBCharacterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutationJ Biol Chem2002277479804799012374800
   PubMed Web of Science ®Google Scholar
• ChenZSRobeyRWBelinskyMGTransport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transportCancer Res2003634048405412874005
   PubMed Web of Science ®Google Scholar
• EjendalKFDiopNKSchweigerLCHrycynaCAThe nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate bindingProtein Sci2006151597160716815914
   PubMed Web of Science ®Google Scholar
• HazaiEBikadiZHomology modeling of breast cancer resistance protein (ABCG2)J Struct Biol2008162637418249138
   PubMed Web of Science ®Google Scholar
• LiYFPolgarOOkadaMEsserLBatesSEXiaDTowards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: a molecular modeling studyJ Mol Graph Model20072583785117027309
   PubMed Web of Science ®Google Scholar
• MiwaMTsukaharaSIshikawaEAsadaSImaiYSugimotoYSingle amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectantsInt J Cancer200310775776314566825
   PubMed Web of Science ®Google Scholar
• RosenbergMFBikadiZChanJThe human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantroneStructure20101848249320399185
   PubMed Web of Science ®Google Scholar
• CaiXBikadiZNiZRole of basic residues within or near the predicted transmembrane helix 2 of the human breast cancer resistance protein in drug transportJ Pharmacol Exp Ther201033367068120203106
   PubMed Web of Science ®Google Scholar
• KageKTsukaharaSSugiyamaTDominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerizationInt J Cancer20029762663011807788
   PubMed Web of Science ®Google Scholar
• DoyleLARossDDMultidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)Oncogene2003227340735814576842
   PubMed Web of Science ®Google Scholar
• HenriksenUFogJULitmanTGetherUIdentification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2J Biol Chem2005280369263693416107343
   PubMed Web of Science ®Google Scholar
• McDevittCACollinsRFConwayMPurification and 3D structural analysis of oligomeric human multidrug transporter ABCG2Structure2006141623163217098188
   PubMed Web of Science ®Google Scholar
• XieYXuKLinnDEThe 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cellsJ Biol Chem20082833349335618056989
   PubMed Web of Science ®Google Scholar
• TakadaTSuzukiHGotohYSugiyamaYRegulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cellsDrug Metab Dispos20053390590915843490
   PubMed Web of Science ®Google Scholar
• KondoCSuzukiHItodaMFunctional analysis of SNPs variants of BCRP/ABCG2Pharm Res2004211895190315553238
   PubMed Web of Science ®Google Scholar
• YanaseKTsukaharaSMitsuhashiJSugimotoYFunctional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor developmentCancer Lett2006234738016303243
   PubMed Web of Science ®Google Scholar
• TamuraAWakabayashiKOnishiYRe-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2Cancer Sci20079823123917297656
   PubMed Web of Science ®Google Scholar
• DiopNKHrycynaCAN-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membraneBiochemistry2005445420542915807535
   PubMed Web of Science ®Google Scholar
• Wakabayashi-NakaoKTamuraAFurukawaTNakagawaHIshikawaTQuality control of human ABCG2 protein in the endoplasmic reticulum: ubiquitination and proteasomal degradationAdv Drug Deliv Rev200961667219111842
   PubMed Web of Science ®Google Scholar
• WakabayashiKNakagawaHTamuraAIntramolecular disulfide bond is a critical check point determining degradative fates of ATP-binding cassette (ABC) transporter ABCG2 proteinJ Biol Chem2007282278412784617686774
   PubMed Web of Science ®Google Scholar
• HonjoYMorisakiKHuffLMSingle-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1)Cancer Biol Ther2002169670212642696
   PubMed Web of Science ®Google Scholar
• SugimotoYTsukaharaSIshikawaEMitsuhashiJBreast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamicsCancer Sci20059645746516108826
   PubMed Web of Science ®Google Scholar
• CascorbiIRole of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugsPharmacol Ther200611245747316766035
   PubMed Web of Science ®Google Scholar
• ImaiYNakaneMKageKC421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistanceMol Cancer Ther2002161161612479221
   PubMed Web of Science ®Google Scholar
• YoshiokaSKatayamaKOkawaCThe identification of two germ-line mutations in the human breast cancer resistance protein gene that result in the expression of a low/non-functional proteinPharm Res2007241108111717373578
   PubMed Web of Science ®Google Scholar
• ItodaMSaitoYShiraoKEight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacanDrug Metab Pharmacokinet20031821221715618737
   PubMedGoogle Scholar
• KobayashiDIeiriIHirotaTFunctional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placentaDrug Metab Dispos2005339410115475413
   PubMed Web of Science ®Google Scholar
• de JongFAMarshSMathijssenRHABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan dispositionClin Cancer Res2004105889589415355921
   PubMed Web of Science ®Google Scholar
• SparreboomAGelderblomHMarshSDiflomotecan pharmacokinetics in relation to ABCG2 421C>A genotypeClin Pharmacol Ther200476384415229462
   PubMed Web of Science ®Google Scholar
• MizuaraiSAozasaNKotaniHSingle nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2Int J Cancer200410923824614750175
   PubMed Web of Science ®Google Scholar
• NakagawaHTamuraAWakabayashiKUbiquitin-mediated proteasomal degradation of non-synonymous SNP variants of human ABC transporter ABCG2Biochem J200841162363118237272
   PubMed Web of Science ®Google Scholar
• ZamberCPLambaJKYasudaKNatural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestinePharmacogenetics200313192812544509
   PubMedGoogle Scholar
• BackstromGTaipalensuuJMelhusHGenetic variation in the ATP-binding cassette transporter gene ABCG2 (BCRP) in a Swedish populationEur J Pharm Sci20031835936412694888
   PubMed Web of Science ®Google Scholar
• PoonkuzhaliBLambaJStromSAssociation of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphismsDrug Metab Dispos20083678079518180275
   PubMed Web of Science ®Google Scholar
• WangFLiangYJWuXPPrognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemiaEur J Cancer2011471990199921531129
   PubMed Web of Science ®Google Scholar
• NakanishiTBailey-DellKJHasselBANovel 5′ untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usageCancer Res2006665007501116707421
   PubMed Web of Science ®Google Scholar
• MaliepaardMSchefferGLFaneyteIFSubcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissuesCancer Res2001613458346411309308
   PubMed Web of Science ®Google Scholar
• AronicaEGorterJARedekerSLocalization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brainEpilepsia20054684985715946326
   PubMed Web of Science ®Google Scholar
• FetschPAAbatiALitmanTLocalization of the ABCG2 mitoxantrone resistance-associated protein in normal tissuesCancer Lett2006235849215990223
   PubMed Web of Science ®Google Scholar
• MarchettiSde VriesNABuckleTEffect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/-(triple-knockout) and wild-type miceMol Cancer Ther200872280228718723475
   PubMed Web of Science ®Google Scholar
• FurmanWLNavidFDawNCTyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumorsJ Clin Oncol2009274599460419687340
   PubMed Web of Science ®Google Scholar
• DingXWWuJHJiangCPABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapyLife Sci20108663163720159023
   PubMed Web of Science ®Google Scholar
• ZhouSMorrisJJBarnesYLanLSchuetzJDSorrentinoBPBcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivoProc Natl Acad Sci U S A200299123391234412218177
   PubMed Web of Science ®Google Scholar
• KatayamaRKoikeSSatoSSugimotoYTsuruoTFujitaNDofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug exportCancer Sci20091002060206819673889
   PubMed Web of Science ®Google Scholar
• SarkadiBHomolyaLSzakacsGVaradiAHuman multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense systemPhysiol Rev2006861179123617015488
   PubMed Web of Science ®Google Scholar
• JonkerJWBuitelaarMWagenaarEThe breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyriaProc Natl Acad Sci U S A200299156491565412429862
   PubMed Web of Science ®Google Scholar
• KrishnamurthyPRossDDNakanishiTThe stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with hemeJ Biol Chem2004279242182422515044468
   PubMed Web of Science ®Google Scholar
• WoodwardOMKottgenACoreshJBoerwinkleEGugginoWBKottgenMIdentification of a urate transporter, ABCG2, with a common functional polymorphism causing goutProc Natl Acad Sci U S A2009106103381034219506252
   PubMed Web of Science ®Google Scholar
• MatsuoHTakadaTIchidaKCommon defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese populationSci Transl Med200915ra11
   PubMed Web of Science ®Google Scholar
• SuzukiMSuzukiHSugimotoYSugiyamaYABCG2 transports sulfated conjugates of steroids and xenobioticsJ Biol Chem2003278226442264912682043
   PubMed Web of Science ®Google Scholar
• NakatomiKYoshikawaMOkaMTransport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cellsBiochem Biophys Res Commun200128882783211688982
   PubMed Web of Science ®Google Scholar
• van HerwaardenAEJonkerJWWagenaarEThe breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridineCancer Res2003636447645214559835
   PubMed Web of Science ®Google Scholar
• HiranoMMaedaKMatsushimaSNozakiYKusuharaHSugiyamaYInvolvement of BCRP (ABCG2) in the biliary excretion of pitavastatinMol Pharmacol20056880080715955871
   PubMed Web of Science ®Google Scholar
• van HerwaardenAESchinkelAHThe function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxinsTrends Pharmacol Sci200627101616337280
   PubMed Web of Science ®Google Scholar
• van HerwaardenAEWagenaarEKarnekampBMerinoGJonkerJWSchinkelAHBreast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milkCarcinogenesis20062712313016000399
   PubMed Web of Science ®Google Scholar
• SawyersCTargeted cancer therapyNature200443229429715549090
   PubMed Web of Science ®Google Scholar
• KrauseDSVan EttenRATyrosine kinases as targets for cancer therapyN Engl J Med200535317218716014887
   PubMed Web of Science ®Google Scholar
• CapdevilleRBuchdungerEZimmermannJMatterAGlivec (STI571, imatinib), a rationally developed, targeted anticancer drugNat Rev Drug Discov2002149350212120256
   PubMed Web of Science ®Google Scholar
• GorreMEMohammedMEllwoodKClinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplificationScience200129387688011423618
   PubMed Web of Science ®Google Scholar
• ShannonKMResistance in the land of molecular cancer therapeuticsCancer Cell200229910212204529
   PubMed Web of Science ®Google Scholar
• AzamMLatekRRDaleyGQMechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABLCell200311283184312654249
   PubMed Web of Science ®Google Scholar
• DaubHSpechtKUllrichAStrategies to overcome resistance to targeted protein kinase inhibitorsNat Rev Drug Discov200431001101015573099
   PubMed Web of Science ®Google Scholar
• MahonFXBellocFLagardeVMDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line modelsBlood20031012368237312609962
   PubMed Web of Science ®Google Scholar
• IllmerTSchaichMPlatzbeckerUP-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylateLeukemia20041840140814724652
   PubMed Web of Science ®Google Scholar
• HegedusTOrfiLSeprodiAVaradiASarkadiBKeriGInteraction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1Biochim Biophys Acta2002158731832512084474
   PubMed Web of Science ®Google Scholar
• BurgerHNooterKPharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinibCell Cycle200431502150515611623
   PubMed Web of Science ®Google Scholar
• Ozvegy-LaczkaCHegedusTVaradyGHigh-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporterMol Pharmacol2004651485149515155841
   PubMed Web of Science ®Google Scholar
• HoughtonPJGermainGSHarwoodFCImatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitroCancer Res2004642333233715059881
   PubMed Web of Science ®Google Scholar
• BreedveldPPluimDCiprianiGThe effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patientsCancer Res2005652577258215805252
   PubMed Web of Science ®Google Scholar
• LemosCJansenGPetersGJDrug transporters: recent advances concerning BCRP and tyrosine kinase inhibitorsBr J Cancer20089885786218253130
   PubMed Web of Science ®Google Scholar
• BurgerHvan TolHBoersmaAWImatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pumpBlood20041042940294215251980
   PubMed Web of Science ®Google Scholar
• ThomasJWangLClarkREPirmohamedMActive transport of imatinib into and out of cells: implications for drug resistanceBlood20041043739374515315971
   PubMed Web of Science ®Google Scholar
• JordanidesNEJorgensenHGHolyoakeTLMountfordJCFunctional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylateBlood20061081370137316627755
   PubMed Web of Science ®Google Scholar
• LiuWBaerMRBowmanMJThe tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2Clin Cancer Res2007132463247017438106
   PubMed Web of Science ®Google Scholar
• BrendelCScharenbergCDohseMImatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cellsLeukemia2007211267127517519960
   PubMed Web of Science ®Google Scholar
• HiwaseDKSaundersVHewettDDasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implicationsClin Cancer Res2008143881388818559609
   PubMed Web of Science ®Google Scholar
• PolliJWHumphreysJEHarmonKAThe role of efflux and uptake transporters in N-{3-chloro-4-[(3-fluorobenzyl)oxy] phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino} methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactionsDrug Metab Dispos20083669570118216274
   PubMed Web of Science ®Google Scholar
• StewartCFLeggasMSchuetzJDGefitinib enhances the antitumor activity and oral bioavailability of irinotecan in miceCancer Res2004647491749915492275
   PubMed Web of Science ®Google Scholar
• YanaseKTsukaharaSAsadaSIshikawaEImaiYSugimotoYGefitinib reverses breast cancer resistance protein-mediated drug resistanceMol Cancer Ther200431119112515367706
   PubMed Web of Science ®Google Scholar
• CarterTAWodickaLMShahNPInhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinasesProc Natl Acad Sci U S A2005102110111101616046538
   PubMed Web of Science ®Google Scholar
• ElkindNBSzentpeteryZApatiAMultidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib)Cancer Res2005651770177715753373
   PubMed Web of Science ®Google Scholar
• NakamuraYOkaMSodaHGefitinib (“Iressa”, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistanceCancer Res2005651541154615735043
   PubMed Web of Science ®Google Scholar
• CusatisGGregorcVLiJPharmacogenetics of ABCG2 and adverse reactions to gefitinibJ Natl Cancer Inst2006981739174217148776
   PubMed Web of Science ®Google Scholar
• LeggasMPanettaJCZhuangYGefitinib modulates the function of multiple ATP-binding cassette transporters in vivoCancer Res2006664802480716651435
   PubMed Web of Science ®Google Scholar
• KatayamaKShibataKMitsuhashiJNoguchiKSugimotoYPharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signalingAnticancer Res2009291059106519414346
   PubMed Web of Science ®Google Scholar
• ErlichmanCBoernerSAHallgrenCGThe HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug effluxCancer Res20016173974811212277
   PubMed Web of Science ®Google Scholar
• ShiZPengXXKimIWErlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistanceCancer Res200767110121102018006847
   PubMed Web of Science ®Google Scholar
• RudinCMLiuWDesaiAPharmacogenomic and pharmacokinetic determinants of erlotinib toxicityJ Clin Oncol2008261119112718309947
   PubMed Web of Science ®Google Scholar
• KawaharaHNoguchiKKatayamaKMitsuhashiJSugimotoYPharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 geneCancer Sci20101011493150020345483
   PubMed Web of Science ®Google Scholar
• HuSChenZFrankeRInteraction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transportersClin Cancer Res2009156062606919773380
   PubMed Web of Science ®Google Scholar
• MinochaMKhuranaVQinBPalDMitraAKEnhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinibInt J Pharm201243612713422688250
   PubMed Web of Science ®Google Scholar
• HegedusCTruta-FelesKAntalffyGInteraction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistanceBiochem Pharmacol20128426026722548830
   PubMed Web of Science ®Google Scholar
• MittapalliRKVaidhyanathanSSaneRElmquistWFImpact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)J Pharmacol Exp Ther2012342334022454535
   PubMed Web of Science ®Google Scholar
• PollerBIusufDSparidansRWWagenaarEBeijnenJHSchinkelAHDifferential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokineticsDrug Metab Dispos20113972973521282407
   PubMed Web of Science ®Google Scholar
• SenRNatarajanKBhullarJThe novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2Mol Cancer Ther2012112033204422778153
   PubMed Web of Science ®Google Scholar
• HegedusCOzvegy-LaczkaCApatiAInteraction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological propertiesBr J Pharmacol20091581153116419785662
   PubMed Web of Science ®Google Scholar
• TangSCNguyenLNSparidansRWWagenaarEBeijnenJHSchinkelAHIncreased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridarInt J Cancer20141341484149424037730
   PubMed Web of Science ®Google Scholar
• HooijbergJHBroxtermanHJSchefferGLPotent interaction of flavopiridol with MRP1Br J Cancer19998126927610496352
   PubMed Web of Science ®Google Scholar
• RobeyRWMedina-PerezWYNishiyamaKOverexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cellsClin Cancer Res2001714515211205902
   PubMed Web of Science ®Google Scholar
• BoernerSATourneMEKaufmannSHBibleKCEffect of P-glycoprotein on flavopiridol sensitivityBr J Cancer2001841391139611355953
   PubMed Web of Science ®Google Scholar
• JagerWGehringEHagenauerBAustSSenderowiczAThalhammerTThe role of hepatic Mrp2 in the interaction of flavopiridol and bilirubin: impact on therapyInt J Clin Pharmacol Ther20034161061114692715
   PubMedGoogle Scholar
• SeamonJARuggCAEmanuelSRole of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitorMol Cancer Ther200652459246717041089
   PubMed Web of Science ®Google Scholar
• YokotaAKimuraSMasudaSINNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activityBlood200710930631416954504
   PubMed Web of Science ®Google Scholar
• RobeyRWShuklaSSteadmanKInhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structureMol Cancer Ther200761877188517575116
   PubMed Web of Science ®Google Scholar
• NobleMEEndicottJAJohnsonLNProtein kinase inhibitors: insights into drug design from structureScience20043031800180515031492
   PubMed Web of Science ®Google Scholar
• SaitoHHiranoHNakagawaHA new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactionsJ Pharmacol Exp Ther20063171114112416489126
   PubMed Web of Science ®Google Scholar
• EjendalKFHrycynaCADifferential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin AMol Pharmacol20056790291115598974
   PubMed Web of Science ®Google Scholar
• ClarkRKerrIDCallaghanRMultiple drugbinding sites on the R482G isoform of the ABCG2 transporterBr J Pharmacol200614950651516981002
   PubMed Web of Science ®Google Scholar
• HerbstRSFukuokaMBaselgaJGefitinib – a novel targeted approach to treating cancerNat Rev Cancer2004495696515573117
   PubMed Web of Science ®Google Scholar
• CappuzzoFLigorioCJannePAProspective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trialJ Clin Oncol2007252248225517538169
   PubMed Web of Science ®Google Scholar
• RobeyRWPolgarODeekenJToKWBatesSEABCG2: determining its relevance in clinical drug resistanceCancer Metastasis Rev200726395717323127
   PubMed Web of Science ®Google Scholar
• ZhuangYFragaCHHubbardKETopotecan central nervous system penetration is altered by a tyrosine kinase inhibitorCancer Res200666113051131317145877
   PubMed Web of Science ®Google Scholar
• LemosCGiovannettiEZucaliPAImpact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patientsPharmacogenomics20111215917021332310
   PubMed Web of Science ®Google Scholar
• AkasakaKKaburagiTYasudaSImpact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancerCancer Chemother Pharmacol20096669169820035425
   PubMed Web of Science ®Google Scholar
• LiJCusatisGBrahmerJAssociation of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patientsCancer Biol Ther2007643243817312388
   PubMed Web of Science ®Google Scholar
• van ErpNPEechouteKvan der VeldtAAPharmacogenetic pathway analysis for determination of sunitinib-induced toxicityJ Clin Oncol2009274406441219667267
   PubMed Web of Science ®Google Scholar
• KimHRParkHSKwonWSPharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patientsCancer Chemother Pharmacol20137282583524013576
   PubMed Web of Science ®Google Scholar
• Gafter-GviliARamRGafterUShpilbergORaananiPRenal failure associated with tyrosine kinase inhibitors – case report and review of the literatureLeuk Res20093412312719640584
   PubMed Web of Science ®Google Scholar
• LinTSRuppertASJohnsonAJPhase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk diseaseJ Clin Oncol2009276012601819826119
   PubMed Web of Science ®Google Scholar
• HuangWSYangCHSorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patientWorld J Gastroenterol2009154464446619764104
   PubMed Web of Science ®Google Scholar
• Al-KaliAFarooqSTfayliATumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemiaJ Clin Pharm Ther20093460761019744017
   PubMed Web of Science ®Google Scholar
• DohseMScharenbergCShuklaSComparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinibDrug Metab Dispos2010381371138020423956
   PubMed Web of Science ®Google Scholar
• DaiCLTiwariAKWuCPLapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2Cancer Res2008687905791418829547
   PubMed Web of Science ®Google Scholar
• ShuklaSRobeyRWBatesSEAmbudkarSVSunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2Drug Metab Dispos20093735936518971320
   PubMed Web of Science ®Google Scholar
• ZhengLSWangFLiYHVandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport functionPLoS One20094e517219390592
   PubMed Web of Science ®Google Scholar
• JoveletCBenardJForestierFFarinottiRBidartJMGilSInhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicinEur J Pharm Sci20124648449122484209
   PubMed Web of Science ®Google Scholar
• ReynerELSevidalSWestMAIn vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactionsDrug Metab Dispos2013411575158323729661
   PubMed Web of Science ®Google Scholar
• LagasJSvan WaterschootRASparidansRWWagenaarEBeijnenJHSchinkelAHBreast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulationMol Cancer Ther2010931932620103600
   PubMed Web of Science ®Google Scholar
• DurmusSSparidansRWWagenaarEBeijnenJHSchinkelAHOral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridarMol Pharm201293236324523020847
   PubMed Web of Science ®Google Scholar
• WuCPSimHMHuangYHOverexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cellsBiochem Pharmacol20128532533423153455
   PubMed Web of Science ®Google Scholar
• SparreboomALoosWJBurgerHEffect of ABCG2 genotype on the oral bioavailability of topotecanCancer Biol Ther2005465065815908806
   PubMed Web of Science ®Google Scholar
• ZamboniWCRamanathanRKMcLeodHLDisposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypesInvest New Drugs20062439340116505951
   PubMed Web of Science ®Google Scholar
• VolkELSchneiderEWild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporterCancer Res2003635538554314500392
   PubMed Web of Science ®Google Scholar
• WangXFurukawaTNitandaTBreast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitorsMol Pharmacol200363657212488537
   PubMed Web of Science ®Google Scholar